SynthesisHuman vaccines & immunotherapeutics2014
Systematic review of the economic value of diarrheal vaccines.
Synthesis in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Value(s) of Vaccination: Building the Scientific Evidence According to a Value-Based Healthcare Approach.Frontiers in public health · 2022Pooled it
- Global economic evaluation of oral cholera vaccine: A systematic review.Human vaccines & immunotherapeutics · 2018Pooled it
- Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework.PharmacoEconomics · 2018Pooled it
- Programmes for pathology: improving health outcomes for low- and middle-income countries in the artificial intelligence paradigm.International health · 2025Article
- An Overview of the Public Health Challenges in Diagnosing and Controlling Human Foodborne Pathogens.Vaccines · 2023Review
- Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries.Applied health economics and health policy · 2022Review
- Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study.The Lancet. Global health · 2021Article
- Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study.The Lancet. Global health · 2019Article
- Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?Human vaccines & immunotherapeutics · 2019Review
- Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries.Cost effectiveness and resource allocation : C/E · 2018Review
- Reaching every child with rotavirus vaccine: Report from the 10th African rotavirus symposium held in Bamako, Mali.Vaccine · 2017Article
- Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Article
- Current issues and priorities in childhood nutrition, growth, and infections.The Journal of nutrition · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diarrheal disease is a leading cause of child mortality in low-income settings and morbidity across a range of settings. A growing number of studies have addressed the economic value of new and emerging vaccines to reduce this threat. We conducted a systematic review to assess the economic value of diarrheal vaccines targeting a range of pathogens in different settings. The majority of studies focused on the economic value of rotavirus vaccines in different settings, with most of these concluding that vaccination would provide significant economic benefits across a range of vaccine prices. There is also evidence of the economic benefits of cholera vaccines in specific contexts. For other potential diarrheal vaccines data are limited and often hypothetical. Across all target pathogens and contexts, the evidence of economic value focuses the short-term health and economic gains. Additional information is needed on the broader social and long-term economic value of diarrhea vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.